Clinical Trials
51 trialsNCT05139017 2026-05-22
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT07602777 2026-05-22
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
GlaxoSmithKline
Phase 1/2 Not yet recruiting
NCT03182244 2026-05-05
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT05586074 2026-04-28
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Sunshine Lake Pharma Co., Ltd.
Phase 3 Recruiting
NCT06001788 2026-04-14
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1 Recruiting
NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT05561751 2026-02-12
Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
GPCR Therapeutics, Inc.
Phase 2 Completed
NCT03246529 2026-01-15
GENESIS
BioLineRx, Ltd.
Phase 3 Active not recruiting
NCT04240002 2026-01-05
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Astellas Pharma Inc
Phase 1/2 Terminated
NCT06509906 2025-12-18
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
EMD Serono
Phase 1 Terminated
NCT02421939 2025-12-04
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Completed
NCT03646123 2025-08-28
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT03102606 2024-08-29
Protective-1
BeyondSpring Pharmaceuticals Inc.
Phase 3 Completed
NCT02400281 2024-07-03
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04345900 2024-05-16
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
BeyondSpring Pharmaceuticals Inc.
Phase 2 Completed
NCT02626338 2023-12-20
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04584112 2023-03-15
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT02467868 2022-02-14
Efficacy and Safety Study With MYL-1401H and Neulasta
Viatris Inc.
Phase 3 Completed
NCT01840579 2021-06-22
MK-3475-011
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02104427 2021-04-19
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
GPCR Therapeutics, Inc.
Phase 2 Completed
NCT01753453 2021-02-23
An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells
Sanofi
Phase 2 Completed
NCT03294577 2021-01-15
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
BeyondSpring Pharmaceuticals Inc.
Phase 3 Unknown
NCT00821249 2020-10-19
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Pfizer
Phase 1/2 Completed
NCT01248923 2020-09-30
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Array BioPharma
Phase 1 Completed
NCT00462358 2020-09-28
A Study of ARRY-520 in Patients With Advanced Cancer
Array BioPharma
Phase 1 Completed
NCT02124148 2020-04-01
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00211185 2020-03-18
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Eisai Inc.
Phase 2 Completed
NCT00140140 2019-11-26
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
Celgene
Phase 1/2 Terminated
NCT01025284 2019-09-17
A Study for Participants With Small-Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01031368 2019-03-01
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
Nohla Therapeutics, Inc.
Phase 1 Completed
NCT01564784 2019-01-09
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Pfizer
Phase 3 Completed
NCT02282215 2018-09-27
Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia
Cellerant Therapeutics
Phase 2 Completed
NCT01649635 2016-07-06
PROSPECTA
Sanofi
Phase 4 Completed
NCT01297543 2016-07-01
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Cellerant Therapeutics
Phase 1/2 Completed
NCT00395967 2015-05-01
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone
Sanofi
Phase 2 Terminated
NCT01767714 2014-12-09
Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation
Sanofi
Phase 3 Completed
NCT01674855 2014-10-01
PEG-G-CSF
Dong-A ST Co., Ltd.
Phase 3 Completed
NCT01923545 2014-10-01
PEG-G-CSF
Dong-A ST Co., Ltd.
Phase 2 Completed
NCT00103610 2014-03-13
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients
Sanofi
Phase 3 Completed
NCT00103662 2014-03-13
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
Sanofi
Phase 3 Completed
NCT00322387 2014-03-13
Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients
Sanofi
Phase 2 Completed
NCT00322491 2014-03-13
Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
Sanofi
Phase 2 Completed
NCT00322842 2014-03-13
Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
Sanofi
Phase 2 Completed
NCT00396201 2014-03-13
AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease
Sanofi
Phase 2 Completed
NCT00396331 2014-03-13
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts
Sanofi
Phase 2 Completed
NCT00444912 2014-03-13
The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)
Sanofi
Phase 2 Completed
NCT00396266 2014-03-07
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
Sanofi
Phase 2 Completed
NCT01164475 2014-02-25
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms
Sanofi
Phase 4 Completed
NCT01478074 2014-01-03
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
Altor BioScience
Phase 1 Withdrawn
NCT00862134 2013-01-10
Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
Proacta, Incorporated
Phase 2 Terminated